Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 1035-1045

  Svicher, Valentina ^a   Alteri, Claudia ^a   Artese, Anna ^b   Zhang, Jing Maria ^c   Costa, Giosuè ^b   Mercurio, Fabio ^a   D'Arrigo, Roberta ^d   Alcaro, Stefano ^b   Palù, Giorgio ^e   Clementi, Massimo ^f   Zazzi, Maurizio ^g   Andreoni, Massimo ^a   Antinori, Andrea ^d   Lazzarin, Adriano ^h   Ceccherini Silberstein, Francesca ^a   Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Department of Pharmacobiological Sciences   (Italy)

^c YALE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; TYROSINE; UNCLASSIFIED DRUG; V3 PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIMULATION; VIRAL GENETICS; VIRAL TROPISM; VIRUS MUTATION;

BASE SEQUENCE; BAYES THEOREM; CLUSTER ANALYSIS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ANALYSIS, DNA; VIRUS INTERNALIZATION;

EID: 80055074737     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1862     Document Type: Article

References (30)

1. Berger EA, Doms RW, Fenyö EM, et al. A new classification for HIV-1. Nature 1998; 391:240.
2. Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-1623. (Pubitemid 351706746)
3. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005; 13:269-277. (Pubitemid 40779815)
4. MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47:236-241. (Pubitemid 351920626)
5. Hoffman TL, Doms RW. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 1999; 16:57-65. (Pubitemid 29179338)
6. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028. (Pubitemid 41611916)
7. Huang CC, Lam SN, Acharya P, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317:1930-1934. (Pubitemid 47509439)
8. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
9. De Jong JJ, De Ronde A, Keulen W, et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66:6777-6780.
10. Cormier EG, Tran DN, Yukhayeva L, et al. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 2001; 75:5541-5549. (Pubitemid 32488147)
11. Farzan M, Chung S, Li W, et al. Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. J Biol Chem 2002; 277:40397-40402. (Pubitemid 35215614)
12. Nolan KM, Jordan AP, Hoxie JA. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol 2008; 82:664-673.
13. Nolan KM, Del Prete GQ, Jordan AP, et al. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol 2009; 83:3798-3809.
14. Ogert RA, Ba L, Hou Y, et al. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol 2009; 83:12151-12163.
15. Svicher V, D'Arrigo R, Alteri C, et al. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 2010; 33:195-206.
16. Hope ACA. A simplified Monte Carlo significance test procedure. J R Stat Soc [Ser A] 1968; 30:582-598.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Statist Soc B 1995; 57:289-300.
18. Svicher V, Sing T, Santoro MM, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80:7186-7198. (Pubitemid 44025215)
19. Svicher V, Aquaro S, D'Arrigo R, et al. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 2008; 197:1408-1418. (Pubitemid 351706465)
20. Zhang J, Hou T, Wang W, Liu JS. Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance. Proc Natl Acad Sci U S A 2010; 107:1321-1326.
21. Bowers KJ, Chow E, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In SC '06. Proceedings of the 2006 ACM/IEEE conference on Supercomputing. New York: ACM 2006.
22. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996; 118:11225-11236. (Pubitemid 26399746)
23. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001; 105:6474-6487. (Pubitemid 35339015)
24. Trott O, Olson JA. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31:455-461.
25. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980; 36:3219-3228.
26. Bozek K, Thielen A, Sierra S, et al. V3 loop sequence space analysis suggests different evolutionary patterns of CCR5-and CXCR4-tropic HIV. PLoS ONE 2009; 4:e7387.
27. Yang X, Tomov V, Kurteva S, et al. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol 2004; 78:12975-12986. (Pubitemid 39507805)
28. Suphaphiphat P, Thitithanyanont A, Paca-Uccaralertkun S, Essex M, Lee TH. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol 2003; 77:3832-3837. (Pubitemid 36297302)
29. Huang W, Frantzell A, Toma J, et al. Defining evolutionary pathways and genetic barriers to CXCR4-mediated entry by HIV type 1. Antivir Ther 2010; 15 Suppl 2:A019.
30. Svicher V, Alteri C, Artese A, et al. Specific genetic signatures in V3 base can modulate co-receptor usage in vivo, the interaction with neutralizing antibodies, and HIV-1 cytopathic effect. 1st International HIV and Viral Hepatitis Virus Workshop. 8-12 June 2010, Dubrovnik, Croatia. Abstract 12.